XSHE
002622
Market cap307mUSD
Oct 09, Last price
2.52CNY
1D
2.86%
1Q
16.67%
Jan 2017
-82.72%
IPO
-42.24%
Name
Whole Shine Medical Technology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Rongyu Group Co., Ltd. is a Chinese enterprise operating across a diverse range of sectors, including power infrastructure solutions, data-driven credit intelligence, and comprehensive financial services. Within its electrical equipment division, the company supplies products such as electronic control complete sets, permanent magnet low and high voltage switchgear, and electronic energy meters, in addition to offering automatic control system integration services. Its credit segment focuses on providing specialized credit assessment services. Furthermore, Rongyu Group's banking operations deliver a broad spectrum of financial solutions, encompassing corporate, personal, and small-to-medium enterprise (SME) finance, alongside capital markets and international banking activities. The company also extends its portfolio to include leasing services for equipment, real estate, and land use rights. Established in 1986, the firm was originally incorporated as Jilin Yongda Group Co., Ltd. before adopting its current name, Rongyu Group Co., Ltd., in November 2016. Its headquarters are located in Beijing, China.
Key people
Qiang Deng
Chief Financial Officer
Lu Lu
Chairman of the Board, Acting General Manager · since 2022
Yuhua Dong
Deputy General Manager, Chief Engineer
Zhongmin Liu
Deputy General Manager, Chief Engineer
Long Wang
Deputy General Manager
Guiqin Wang
Deputy General Manager
Feng Zhao
Deputy General Manager, Director
Director · since 2023
Yiren Gao
Director
Xiangwen Li
Director
Haitao Li
Director · since 2012
Zhengxue Ma
Deputy General Manager, Director · since 2016
Zhanbin Niu
Director · since 2022
Bo Han
Independent Director
Gang Mu
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||